drugset / Trial / NCT02465528
Ceritinib Rare Indications Study in ALK+ Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is Proof-of-Concept (POC) study to assess the preliminary antitumor activity and safety and tolerablity using ceritinib (LDK378) in the treatment of life threatening tumors that are characterized by ALK genetic alteration (and/or overexpression in some diseases).
Timeline
- Start
- 2016-05-06
- Primary completion
- 2018-08-20
- Completion
- 2018-08-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ceritinib | Small molecule | 750 mg | Oral |